Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4 Fresh inflation data looks to keep ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2024 sales and earnings conference call with institutional investors and analysts at ...

EVX-01 is designed with Evaxion’s AI-Immunology™ platform and tailored to target the unique tumor profile and immune ...

Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, Jan. 13, 2025, ...

Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sarcoma reaches ...

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...

Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH ...

DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ ...

Giorgio Massimini formerly Vice President Merck KGaA. Over 30 years of experience in leading ... Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger ...

This important study reveals a role for IκBα in the regulation of embryonic stem cell pluripotency. The solid data in mouse embryonic stem cells include separation of function mutations in IκBα to ...

Daiichi Sankyo to pay $132.5 million to acquire IP rights for anti-TAMUC1 antibody in DS-3939 from Glycotope: Tokyo Wednesday, January 15, 2025, 09:00 Hrs [IST] Daiichi Sankyo Com ...

PLYMOUTH, MA, USA I January 13, 2025 I GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK ...